



## Emerging Biomarkers for Immune Checkpoint Inhibitors in Tumors

Guest Editors:

**Dr. Honglei Chen**

Department of Pathology, School of Medicine, Wuhan University, Wuhan 430071, China

**Dr. Hitoshi Dejima**

Department of Surgery, Division of General Thoracic Surgery, Teikyo University School of Medicine, Tokyo 173-8605, Japan

**Dr. Min Peng**

Department Oncology, Renmin Hospital, Wuhan University, Wuhan 430071, China

Deadline for manuscript submissions:

**closed (20 May 2023)**

### Message from the Guest Editors

Immune checkpoint inhibitors (ICIs) have recently taken off as promising immuno-therapeutic methods that have slowed down the progress of various cancers and equipped patients with survival advantages. However, the long-term respondents tally is less than 20% of the population. This low response rate warrants the need for biomarkers which can dynamically provide insight into the possible response of patients to ICIs. Biomarkers are biological molecules that predict the pathological state of patients and the potential response they will elicit to ICIs. Predictive biomarkers play a crucial role in analyzing the effects of ICI therapy on patients and potentially filtering outpatients who will certainly benefit from ICIs. Potential biomarkers for cancer immunotherapy, such as PD-1/PD-L1, total mutation burden (TMB), and tumor-infiltrating lymphocytes (TILs), etc., may be used to assist future application of immunotherapy and patient selection in clinical practice.

The aim of this Special Issue is to look into the emerging biomarkers for immune checkpoint inhibitors in tumors. We welcome both original research articles and reviews.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Andreas Kjaer

Department of Clinical  
Physiology, Nuclear Medicine &  
PET National University Hospital,  
Rigshospitalet, University of  
Copenhagen, Blegdamsvej 9, DK-  
2100 Copenhagen, Denmark

## Message from the Editor-in-Chief

You are cordially invited to submit research articles, short communications, comprehensive reviews, case reports or interesting images for consideration and publication in *Diagnostics* (ISSN 2075-4418). *Diagnostics* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. We would be pleased to welcome you as one of our authors.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, Inspec, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Internal Medicine)

## Contact Us

---

*Diagnostics* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/diagnostics](http://mdpi.com/journal/diagnostics)  
[diagnostics@mdpi.com](mailto:diagnostics@mdpi.com)  
[X@diagnostic\\_mdpi](https://twitter.com/diagnostic_mdpi)